Design of the EMPERIAL-preserved trial of empagliflozin in patients with chronic heart failure with preserved ejection fraction

被引：0
|
作者：
Ponikowski, P. [1 ]
Abraham, W. T. [2 ]
Lindenfeld, J. [3 ]
Zeller, C. [4 ]
Macesic, H. [5 ]
Brueckmann, M. [6 ]
Salsali, A. [7 ]
Anker, S. D. [8 ]
机构：
[1] Wroclaw Med Univ, Wroclaw, Poland
[2] Ohio State Univ, Columbus, OH 43210 USA
[3] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[4] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
[5] Boehringer Ingelheim Canada Ltd, Burlington, ON, Canada
[6] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
[7] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT USA
[8] Charite, Berlin, Germany
来源：
EUROPEAN JOURNAL OF HEART FAILURE | 2018年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P269
引用
收藏
页码：48 / 49
页数：2
相关论文
共 50 条
  • [31] Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age
    Boehm, Michael
    Butler, Javed
    Filippatos, Gerasimos
    Ferreira, Joao Pedro
    Pocock, Stuart J.
    Abdin, Amr
    Mahfoud, Felix
    Brueckmann, Martina
    Gollop, Nicholas D.
    Iwata, Tomoko
    Ponikowski, Piotr
    Wanner, Christoph
    Zannad, Faiez
    Packer, Milton
    Anker, Stefan D.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 80 (01) : 1 - 18
  • [32] Empagliflozin and Elderly Patients With Preserved Ejection Fraction Heart Failure Is Age Just a Number?*
    Sauer, Andrew J.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 80 (01) : 19 - 21
  • [33] The Emperor-Preserved trial: what will change for patients with heart failure with preserved ejection fraction?
    Deaton, Christi
    EUROPEAN JOURNAL OF CARDIOVASCULAR NURSING, 2022, 21 (04) : 293 - 294
  • [34] Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial
    Anker, Stefan D.
    Butler, Javed
    Filippatos, Gerasimos
    Shahzeb Khan, Muhammad
    Pedro Ferreira, Joao
    Bocchi, Edimar
    Bohm, Michael
    Pieter Brunner-La Rocca, Hans
    Choi, Dong-Ju
    Chopra, Vijay
    Chuquiure, Eduardo
    Giannetti, Nadia
    Esteban Gomez-Mesa, Juan
    Janssens, Stefan
    Januzzi, James L.
    Gonzalez-Juanatey, Jose R.
    Merkely, Bela
    Nicholls, Stephen J.
    Perrone, Sergio, V
    Pina, Ileana L.
    Ponikowski, Piotr
    Senni, Michele
    Seronde, Marie-France
    Sim, David
    Spinar, Jindrich
    Squire, Iain
    Taddei, Stefano
    Tsutsui, Hiroyuki
    Verma, Subodh
    Vinereanu, Dragos
    Zhang, Jian
    Jamal, Waheed
    Schnaidt, Sven
    Schnee, Janet M.
    Brueckmann, Martina
    Pocock, Stuart J.
    Zannad, Faiez
    Packer, Milton
    EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 (12) : 2383 - 2392
  • [35] PREDICTORS OF CHRONIC HEART FAILURE WITH PRESERVED EJECTION FRACTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS TREATED WITH EMPAGLIFLOZIN
    Lebedev, Denis
    Lyasnikova, Elena
    Vasilyeva, Elena
    Sitnikova, Maria
    Babenko, Alina
    JOURNAL OF HYPERTENSION, 2022, 40 (SUPPL) : E190 - E190
  • [36] PREDICTORS OF CHRONIC HEART FAILURE WITH PRESERVED EJECTION FRACTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS TREATED WITH EMPAGLIFLOZIN
    Lebedev, Denis
    Lyasnikova, Elena
    Vasilyeva, Elena
    Sitnikova, Maria
    Babenko, Alina
    JOURNAL OF HYPERTENSION, 2022, 40 (SUPPL 1) : E190 - E190
  • [37] Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection: The EMPEROR-Preserved Trial
    Butler, Javed
    CIRCULATION, 2021, 144 (25) : E585 - E586
  • [38] Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR-Preserved
    Coats, Andrew J. S.
    Butler, Javed
    Tsutsui, Hiroyuki
    Doehner, Wolfram
    Filippatos, Gerasimos
    Ferreira, Joao Pedro
    Boehm, Michael
    Chopra, Vijay K.
    Verma, Subodh
    Nordaby, Matias
    Iwata, Tomoko
    Nitta, Daisuke
    Ponikowski, Piotr
    Zannad, Faiez
    Packer, Milton
    Anker, Stefan D.
    JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, 2024, 15 (01) : 412 - 424
  • [39] Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction A Post Hoc Analysis of the EMPEROR-Preserved Trial
    Butler, Javed
    Usman, Muhammad Shariq
    Filippatos, Gerasimos
    Ferreira, Joao Pedro
    Boehm, Michael
    Brueckmann, Martina
    Januzzi, James L.
    Kaul, Sanjay
    Pina, Ileana L.
    Ponikowski, Piotr
    Senni, Michele
    Sumin, Mikhail
    Verma, Subodh
    Zaremba-Pechmann, Liliana
    Pocock, Stuart J.
    Packer, Milton
    Anker, Stefan
    JAMA CARDIOLOGY, 2023, 8 (07) : 640 - 649
  • [40] Effects of empagliflozin in patients with heart failure and preserved ejection fraction according to baseline diuretic use: results from the EMPEROR-Preserved trial
    Butler, J.
    EUROPEAN HEART JOURNAL, 2022, 43 : 982 - 982
12345